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Skeletal, cardiac, and respiratory muscle
function and histopathology in the
P448Lneo− mouse model of FKRP-deficient
muscular dystrophy
Qing Yu1, Melissa Morales2, Ning Li2, Alexander G. Fritz2, Ren Ruobing3, Anthony Blaeser4, Ershia Francois1,
Qi-Long Lu4, Kanneboyina Nagaraju2 and Christopher F. Spurney5*

Abstract
Background: Fukutin-related protein (FKRP) mutations are the most common cause of dystroglycanopathies known
to cause both limb girdle and congenital muscular dystrophy. The P448Lneo− mouse model has a knock-in mutation
in the FKRP gene and develops skeletal, respiratory, and cardiac muscle disease.
Methods: We studied the natural history of the P448Lneo− mouse model over 9 months and the effects of twice
weekly treadmill running. Forelimb and hindlimb grip strength (Columbus Instruments) and overall activity (Omnitech
Electronics) assessed skeletal muscle function. Echocardiography was performed using VisualSonics Vevo 770 (FujiFilm
VisualSonics). Plethysmography was performed using whole body system (ADInstruments). Histological evaluations
included quantification of inflammation, fibrosis, central nucleation, and fiber size variation.
Results: P448Lneo− mice had significantly increased normalized tissue weights compared to controls at 9 months of age
for the heart, gastrocnemius, soleus, tibialis anterior, quadriceps, and triceps. There were no significant differences seen in
forelimb or hindlimb grip strength or activity monitoring in P448Lneo− mice with or without exercise compared to
controls. Skeletal muscles demonstrated increased inflammation, fibrosis, central nucleation, and variation in fiber size
compared to controls (p < 0.05) and worsened with exercise. Plethysmography showed significant differences in respiratory
rates and decreased tidal and minute volumes in P448Lneo− mice (p < 0.01). There was increased fibrosis in the
diaphragm compared to controls (p < 0.01). Echocardiography demonstrated decreased systolic function in 9-monthold mutant mice (p < 0.01). There was increased myocardial wall thickness and mass (p < 0.001) with increased fibrosis
in 9-month-old P448Lneo− mice compared to controls (p < 0.05). mRNA expression for natriuretic peptide type A
(Nppa) was significantly increased in P448Lneo− mice compared to controls at 6 months (p < 0.05) and for natriuretic
peptide type B (Nppb) at 6 and 9 months of age (p < 0.05).
Conclusions: FKRP-deficient P448Lneo− mice demonstrate significant deficits in cardiac and respiratory functions
compared to control mice, and this is associated with increased inflammation and fibrosis. This study provides new
functional outcome measures for preclinical trials of FKRP-related muscular dystrophies.
Keywords: Limb-girdle muscular dystrophy, Congenital muscular dystrophy, Fukutin related protein (FKRP), P448Lneo− mice,
Echocardiography, Plethysmography, Preclinical trials
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Background
Muscular dystrophies are a heterogeneous group of
disorders characterized by progressive muscle weakness and can also affect the respiratory, cardiac, and
central nervous systems. The clinical phenotype and
prognosis vary significantly making the diagnosis and
treatment different for each disease. However, the
continued identification of specific genetic causes for
the more common muscular dystrophies has led to a
better understanding of disease pathogenesis and new
therapeutic strategies [1].
One pathogenic mechanism of muscular dystrophies
lies in the disruption of the dystrophin-glycoprotein
complex (DGC) [2]. The DGC is responsible for linking
the sarcolemmal membrane with the extracellular matrix
(ECM) and transmitting contraction forces to maintain
muscle cell membrane integrity [3]. The DGC is composed of multiple proteins including dystrophin, dystroglycans, multiple sarcoglycans, dystrobrevin, laminin,
and collagens. Without even one of these proteins,
membranes can tear and activate multiple pathogenic
pathways that lead to cell death.
Alpha-dystroglycan (α-DG) is one component of the
DCG and interacts with proteins in the ECM including laminin, perlecan, agrin, neurexin using glycosylated O-mannose sugar moieties [4]. Defective
glycosylation of α-DG is the pathogenic basis of several muscular dystrophy subtypes known as dystroglycanopathies, including limb-girdle muscular dystrophy
(LGMD) and congenital muscular dystrophy (CMD).
These subtypes demonstrate heterogeneous phenotypes that can range from early presentations with
severe eye and brain disease to more mild skeletal
muscle disease in older patients. More than 17 genes
are involved in the pathogenesis including POMT1,
POMT2, POMGnT, FKRP, Fukutin, and LARGE acting
as glycosyl-transferases in the O-mannosylation of αDG [5]. The severity of disease is thought to be related to the effect of each mutation on degree of
glycosylation and laminin binding ability [6]. FKRP is
a gene that encodes fukutin-related protein and its
mutations cause dystroglycanopathies of both LGMD
and CMD phenotypes as well as muscle-eye-brain and
Walker-Warburg syndrome [7–11]. FKRP has recently
been demonstrated as a ribitol 5-phosphate transferase in the synthesis pathway of laminin binding glycan of α-DG [12].
Multiple mouse models were developed to study the
role of FKRP and experimental therapies. These
models show a range of phenotypes consistent with
human FKRP diseases. In general, the severity of the
reported mouse models follows the same trend as the
severity observed in patients with the same mutations.
Ackroyd et al. (2009) developed the model FKRP-
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NeoTyr307Asn that demonstrated reduced levels of
FKRP transcript. However, the mutant mice died soon
after birth and were therefore not useful for
experimental therapy development [13]. Mouse
models with the common mutation L276I were
created by several groups [14–16]. However,
dystrophic phenotype of the mutant mice is very mild
with clearly observable pathology only after 6 months
of age without significant involvement of respiratory
and cardiac muscles, apparently milder than
phenotype in patients with the same homozygous
mutations. Another reported FKRP mutant mouse
model contains P448L mutation associated with
congenital muscular dystrophy type 1C (MDC1C) in
clinic [8, 17]. The knock-in FKRP P448L (with neo
cassette removed, referred as P448Lneo− mouse)
homozygous mouse has been reported with a severe
phenotype consistent with severe LGMD2I, but milder
than MDC1C as almost all newborn mice survive and
have a life-span of more than 1 year with near normal breeding capacity [18]. Also important, the
mouse was reported to show involvement of respiratory and cardiac muscles with progressive fibrosis
[16]. Blaeser et al. (2016) examined the P448Lneo−
mouse and demonstrated increased diaphragmatic fibrosis and decreased cardiac function by 12 months
of age [19]. This pattern of phenotype represents well
the clinic manifestation of dystroglycanopathies, as a
proportion of the patient population is associated
with pulmonary and cardiac disease. Clinically, Pane
et al. (2012) described cardiac involvement in 6% and
pulmonary involvement in 12% of patients with congenital muscular dystrophies [20]. And significant cardiac disease can be seen in LGMD 2I, even leading to
cardiac transplantation [21–23]. More recently, a
study by Maricelli et al. also demonstrated cardiac
dysfunction with and without exercise [24]. We consider the P448Lneo− mouse highly relevant and valuable for developing experimental therapies to FKRP
dystroglycanopathy. Therefore, validation of the skeletal muscle phenotype and further characterization of
respiratory and cardiac muscle are essential.

Methods
Animal care

This study was carried out in strict accordance with
the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes
of Health. All experiments were performed in accordance with Children’s National Health System IACUC
approved protocol #30432. P448Lneo− homozygous
male mice were generated in McColl Lockwood
Laboratory (Charlotte, NC) and rederived and
imported from Jackson Laboratory (Bar Harbor, ME)
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Table 1 Timeline of experimental procedures performed on groups A, B, C, D of P448Lneo− and control mice. Groups A, B, and D
were composed of P448Lneo− (n = 8) and control (n = 8) mice. Group C was composed of P448Lneo− (n = 8), exercised P448Lneo−
(n = 12), and control (n = 8) mice. Group A was studied at 1 month of age. Group B was studied at 2 months of age. Group C was
studied every month until age 6 months of age. A group of P448Lneo− mice underwent exercise treadmill running until 6 months
of age. Control mice did not undergo exercise testing. Group D was studied until 9 months of age
Group

A

B

C

Timeline (months of age)

1

2

1

2

3

4

5

6

x

x

x

x

x

x

Treadmill exercise
(2×/week only P448Lneo− mice)
Body weight

x

x

D
9

x

x

x

x

x

x

x

Grip strength test

x

x

x

x

x

x

x

Digiscan activity

x

x

x

x

x

Echocardiography
Plethysmography

x

x

x

x

x

x

x

x

Serum creatinine kinase

x

x

x

x

Histology

x

x

x

x

Fibrosis

x

x

x

x

[18]. Age-matched male C57BL/6J (referred to as control, C57, or BL6) mice were purchased from Jackson
Laboratory. Animals were ear tagged prior to group
assignment and were housed in cages of standard dimension on ground corn cob bedding mixed with a
soft recycled shredded paper (nesting material) called
Tek Fresh. The animals were housed in a temperature
controlled (20–24 °C) colony room with a 12-h light/
dark cycle and received mouse chow and water ad
libitum. No animals were euthanized prior to reaching
end of study criteria.

Experimental procedure
Groups A, B, and D were composed of P448Lneo−
(n = 8) and control (n = 8) mice. Group C was composed of P448Lneo− (n = 8), exercised P448Lneo−
(n = 12), and control (n = 8) mice. Group A was
studied at 1 month of age when the skeletal muscle

pathology becomes detectable. Group B was studied at
2 months of age. Group C was studied every month
until 6 months of age. A 1-month interval was chosen
with the aim to identify the peak of muscle degeneration and severity as the disease progresses. A separate
group of P448Lneo− mice underwent exercise treadmill running until 6 months of age. Control mice did
not undergo exercise testing. Group D was studied at
9 months of age when both histological and functional
data have already shown severe and detectable defects.
Table 1 shows the timing of different testing for each
group.
Treadmill

The mice were placed on the treadmill (Columbus Instruments, Columbus, OH) twice a week, one per lane
for 30 min running at 12 m per minute speed per
TREAT-NMD SOP for chronic exercise protocol in

Table 2 Body, muscle, and organ weights normalized by body weight in P448Lneo− (FKRP) and control (BL6) mice showing
significant differences at 6 and 9 months of age
Weight
(n = 8)

1 month
BL6

FKRP

2 months
BL6

FKRP

6 months
BL6

FKRP

9 months
BL6

FKRP

Body (g)

19 ± 1.2

19.6 ± 0.9

21.9 ± 1.5

22.3 ± 0.83

28 ± 1.7

30 ± 1.2

33 ± 6.0

31 ± 1.7

GAS/BW(10−6)

6.2 ± 0.5

6.3 ± 0.3

6.4 ± 0.4

6.5 ± 0.4

5.4 ± 1

6.0 ± 0.2***

5.0 ± 0.2

6.3 ± 0.5***

Sol/BW(10−7)

3.7 ± 0.3

3.7 ± 0.2

3.8 ± 0.9

3.6 ± 0.5

3.0 ± 0.4

3.5 ± 0.2*

3.3 ± 0.3

4.1 ± 0.4**

TA/BW(10−6)

2.4 ± 0.4

2.3 ± 0.2

2.3 ± 0.1

2.3 ± 0.2

1.8 ± 0.2

2.2 ± 0.2***

1.4 ± 0.2

2.0 ± 0.3***

Triceps/BW(10−6)

4.1 ± 0.4

4.4 ± 0.4

4.4 ± 0.6

4.3 ± 0.4

3.4 ± 0.6

4.5 ± 0.3***

3.3 ± 0.6

5.4 ± 0.9***

Quad/BW(10 )

7.0 ± 0.2

7.3 ± 1.1

5.7 ± 0.8

6.0 ± 0.8

5.3 ± 0.8

6.5 ± 0.9*

5.0 ± 0.9

6.3 ± 0.4**

Heart/BW(10−6)

5.0 ± 0.2

5.3 ± 0.5

5.1 ± 0.2

5.2 ± 0.4

4.3 ± 0.3

4.4 ± 0.2

3.9 ± 0.5

4.4 ± 0.4*

21 ± 1.2

20 ± 3.6

20 ± 1.4

19 ± 1

16 ± 1.2

15 ± 0.5*

14.5 ± 2.8

14.2 ± 0.1

−6

−6

Brain/BW(10 )

*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; using t test when compared to BL6 control mice at same age. Data presented as mean ± SD. GAS gastrocnemius,
Sol soleus, TA tibialis anterior, Quad quadriceps, BW body weight
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Table 3 Body, muscle, and organ weights normalized by body weights among groups of P448Lneo− (FKRP) without and with
treadmill exercise (FKRP-treadmill) and control (BL6) mice at 6 months of age
Measurement

BL6 control

FKRP

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

8

28 ± 1.7

8

30 ± 1.2

12

29 ± 1.8

NS

GAS/BW(10 )

8

5.4 ± 0.3

8

6.0 ± 0.2

12

6.4 ± 0.7

BL6 vs FKRP: p < 0.05,
BL6 vs FKRP-treadmill: p < 0.001

Sol/BW(10−7)

8

3.0 ± 0.4

8

3.5 ± 0.2

12

3.4 ± 0.3

BL6 vs FKRP: p < 0.05,
BL6 vs FKRP-treadmill: p < 0.05.

TA/BW(10−6)

8

1.8 ± 0.2

8

2.2 ± 0.2

12

2.4 ± 0.3

BL6 vs FKRP: p < 0.01,
BL6 vs FKRP-treadmill: p < 0.001

Triceps/BW(10−6)

8

3.4 ± 0.6

8

4.5 ± 0.3

12

5.2 ± 0.7

BL6 vs FKRP: p < 0.01,
BL6 vs FKRP-treadmill: p < 0.0001
FKRP vs FKRP-treadmill: p < 0.05

Quad/BW(10−6)

8

5.3 ± 0.8

8

6.5 ± 0.9

12

7.0 ± 1.3

BL6 vs FKRP: p < 0.05,
BL6 vs FKRP-treadmill: p < 0.01

Body (g)
−6

FKRP-treadmill

Significantly different groups
(adjusted p values using ANOVA
followed by post hoc analysis)

Heart/BW(10−6)

8

4.3 ± 0.3

8

4.4 ± 0.2

12

4.4 ± 0.5

NS

Brain/BW(10−6)

8

16 ± 1.2

8

15 ± 0.5

12

16 ± 1.2

NS

GAS gastrocnemius, Sol soleus, TA tibialis anterior, Quad quadriceps, BW body weight, NS not significant

dystrophic mice (http://www.treat-nmd.eu/research/preclinical/dmd-sops/). If a mouse rested at the end of the
lane, the animal would be gently pushed back onto the
treadmill surface to restart running. The treadmill tests
started on mice at approximately 1 month of age and
continued until 6 months of age. During the weeks of
measurements including grip strength, activity monitor,
echo, and plethysmography, treadmill running was
avoided.
Grip strength

Forelimb grip strength was measured by a grip strength
meter (Columbus Instruments, Columbus, OH). The
animal was held so that only the forelimb paws grasped
the specially designed mouse flat mesh assembly and the
mouse was pulled back until their grip was broken. The
force transducer retained the peak force reached when
the animal’s grip was broken, and this was recorded
from a digital display. For hindlimb strength, an angled
mesh assembly was used. Mice were allowed to rest on
the angled mesh assembly, facing away from the meter
with its hindlimbs at least one-half of the way down the
length of the mesh. The mouse tail was pulled directly
toward the meter and parallel to the mesh assembly.
During this procedure, the mice resist by grasping the
mesh with all four limbs. Pulling toward the meter was
continued until the hindlimbs released from the mesh
assembly. Five successful hindlimb and forelimb strength
measurements within 2 min were recorded. The maximum values were used for analysis. The grip strength
measurements were collected in the morning hours over
a 5-day period. The mice were trained on the grip
strength meter before the trial [25]. Forelimb and hindlimb maximal muscle strength were obtained as values

of KGF (kilogram-force) and normalized to bodyweights
as “KGF/kg.”
Locomotor activity

Locomotor activity was measured using an open-field
digiscan apparatus (Omnitech Electronics, Columbus,
OH). Total distance, horizontal activity, and vertical activity were recorded every 10 min for 1 h as described
previously [26, 27]. As with the grip strength, the activity
data were collected in the morning hours over a 4-day
period and the mice were trained in the open field apparatus prior to the trial [25].
Echocardiography

Echocardiography was performed and quantitative measurements were made offline using analytic software
(FujiFilm VisualSonics, Toronto, Ontario, Canada) as
previously described [25]. Measurements included vessel
diameters, ventricular chamber size, and blood flow velocities and timing across the atrioventricular and semilunar valves. M-mode images were used to measure left
ventricular (LV) chamber sizes and wall thicknesses. Percent shortening fraction (SF) and ejection fraction (EF)
were calculated from M-mode measurements. Myocardial performance index (MPI) was also calculated from
Doppler measurements.
Plethysmography

The whole body plethysmography system (ADInstruments, St. Paul, MN) utilized a custom mouse chamber developed by the Research Instrument Shop at
the University of Pennsylvania to minimize dead
space. Other components in the system included the
spirometer (ML141), respiratory flow head (MLTL1),
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Fig. 1 Normalized grip strengths for P448Lneo− and control mice. Panel a shows no significant differences in normalized forelimb grip strength
(kilogram force per kilogram; KGF/kg) at 9 months of age in P448Lneo− (FKRP) and control (BL6) mice. Panel b shows no significant differences in
normalized hindlimb grip strength (kilogram force per kilogram; KGF/kg) at 9 months of age in FKRP and control mice. Panel c shows normalized
forelimb and panel d shows normalized hindlimb grip strengths from 1 to 9 months of age for FKRP mice, exercised FKRP mice (FKRP-treadmill;
1–6 months only), and control mice with no significant differences

and the PowerLab 4/30 with LabChart software. The
mouse was brought to the measurement room
15 min before the start of the measurement session
to recover from the transportation and new environment stresses. The spirometer was calibrated every
time the hardware was powered on to read in terms
of flow (ml/s) rather than pressure (mv).Calibration of
the plethysmography was performed with 1 ml of air
injected into the animal chamber to correlate the
injected volume (ml) with the differential pressure
(mv) measured in the chamber by integration. A
700 ml/min flow of dry air through the chambers was
constantly delivered to avoid CO2 and water accumulation and to maintain a constant temperature. The
mouse was weighed and placed into the chamber first
to acclimate for 15 min then the respiratory flow data

was recorded for 10 min. For data analysis, values for
respiratory rate, tidal volume (TV), minute ventilation
(MV), TV normalized by body weight (TV/BW), and
MV normalized by body weight (MV/BW) were recorded using LabChart software.
Blood collection

Blood samples were taken via retro-orbital bleeding
when the animals were euthanized and the serum collected was used for creatinine kinase levels.
Tissue collection and histological evaluations

Animals were sacrificed via inhaled carbon dioxide and
cervical dislocation, and tissue samples were obtained. All
tissue samples were weighed using the Mettler ToLedo
scale (Columbus, OH) prior to processing. Skeletal
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Fig. 2 Inflammation levels (foci/mm2) in P448Lneo− (FKRP) mice gastrocnemius (panel a), quadriceps (panel b), and triceps (panel c) at
1, 2, 6, and 9 months of age compared to controls (BL6) and serum creatinine kinase (CK) at 9 months of age (panel d). Significant increases in
inflammation are seen with a peak at 2 months of age. Serum CK levels are significantly increased at 1, 6, and 9 months. Data presented as
mean ± standard deviation;*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 using t test when compared to BL6 control mice at same age;
###p < 0.001 using two-tailed Mann-Whitney nonparametric test when compared to BL6 control mice at same age

muscles (gastrocnemius, tibialis anterior, soleus, triceps,
and quadriceps) from one side of the animal, half the diaphragm, half the heart, and whole brain were stored in
formalin. The contralateral or other half of muscles were
snapped frozen in isopentane cooled in liquid nitrogen
and stored at − 80 °C for further analysis. Slides were prepared and stained by Histoserv Inc. (Gaithersburg, MD).
Histological evaluations were performed in a blinded
manner using coded slides. One transverse tissue section
per muscle per animal was analyzed. Whole muscle digital
images of the tissues were taken at × 20 using NanoZoomer slide scanner (Hamamatsu Inc., Bridgewater, NJ) and
were opened using NDP.view2 software. Each tissue section was analyzed throughout its entire area. The total
number of inflammation foci (an interstitial group of 10
smaller inflammatory cell dark blue nuclei in a highpower field) was quantified. The entire tissue section area
was measured (mm2), and all counts were normalized to
the tissue area. The parameters including percentage of
fibers with central nucleation and fiber diameter were
measured using MetaMorph Microscopy Automation and
Image Analysis Software on paraffin sections of
gastrocnemius, triceps, quadriceps, and diaphragm.
Quantification of fibrosis

Paraffin sections of gastrocnemius, diaphragm, and heart
tissue were stained with picrosirius red by Histoserv,

Inc. (Germantown, MD). The tissues were magnified
under a light microscope at an objective of 10 x and
digital images obtained using computer software (Olympus C.A.S.T. Stereology System, Olympus America Inc.,
Center Valley, PA). These digital images were processed
using ImageJ (NIH) with additional threshold color
plug-ins to process jpeg images. Pixels corresponding to
the area stained in red were normalized to the total pixel
area of the tissue image, and the results were expressed
as percent of fibrotic area.
mRNA expression analysis

Snapped frozen hearts from 2-, 6-, and 9-month-old
FKRP and BL6 control mice were collected into tubes
with 1 mL of TRIzol and homogenized. Total RNA
was isolated and washed and the RNA yield and purity was determined using a NanoDrop 2000 microvolume spectrophotometer (ThermoFisher). cDNA was
generated using the high-capacity cDNA reverse transcription kit (Applied Biosystems, cat #4368813). The
cDNA was added to TaqMan universal PCR master
mix (Applied Biosystems, cat #4304437), and the following TaqMan Gene Expression Assays (Applied Biosystems): Nppa, Nppb, and Fn1. GAPDH was used as
the reference gene. Real-type PCR was performed
using the CFX384 Touch Real-Time PCR Detection
System and associated software (Bio-Rad).
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Statistical analysis

Data is presented as mean ± standard deviation (SD). Normality of each phenotype was tested using both the
Shapiro-Wilk normality test and visual inspection of histograms except for percent central nucleation and fiber
diameter size as there are only three total samples. All
tested phenotypes were normally distributed except inflammation in quadriceps of 1- and 9-month-old BL6, and
6 months old P448Lneo− excised mice, inflammation in
gastrocnemius of 2-, 6-, and 9-month-old BL6, and 6month-old P448Lneo− excised mice, and inflammation in
Triceps of 2-, 6-, and 9-month-old BL6 mice. For normally
distributed parameters, comparisons were made among
6 –month-old BL6, P448Lneo−, and P448Lneo− excised
mice using analysis of the variance (ANOVA) followed by
Tukey multiple comparison analysis. A single t test was
used to compare the BL6 control group to the P448Lneo−
group. RT-PCR data were normalized to the 2-month-old
BL6 control group and are presented as fold change. For
abnormally distributed parameters, comparisons were
made among 6-month-old BL6, P448Lneo−, and
P448Lneo− excised mice using Kruskal-Wallis test
followed by Dunn’s multiple comparison analysis and a
two-tailed Mann-Whitney test was used to compare the
BL6 control group to the P448Lneo− group. A value of
p < 0.05 was considered statistically significant.

Results
Body, organ, and muscle weights

No significant differences were seen in total body weight
between BL6 (control) and P448Lneo− mice (Table 2).
There was a significant difference in brain weight normalized to body weight at 6 months of age (p < 0.05).
The P448Lneo− heart showed significantly increased
mass when normalized to body weight compared to BL6
at 9 months of age (p < 0.05). The skeletal muscles
gastrocnemius, soleus, tibialis anterior, quadriceps, and
the triceps from mutant mice all demonstrated significantly increased mass normalized to body weight compared to BL6 at 6 and 9 months of age (Table 2).
P448Lneo− mice exercised on the treadmill showed an
increase in normalized muscle weight compared to controls for the soleus, tibialis anterior, triceps, and quadriceps muscles (p < 0.05; Table 3). Exercised P448Lneo−
mice also demonstrated a higher normalized muscle
weight for the triceps compared to unexercised
P448Lneo− mice (p < 0.05).

Skeletal muscle
Grip strength

No significant differences in normalized forelimb or
hindlimb grip strength were seen at 9 months of age between control and P448Lneo− mice (Fig. 1). At 6 months
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of age, exercise had no significant effects on normalized
forelimb or hindlimb grip strength (Fig. 1).
Activity monitor

There were no significant differences between BL6 and
P448Lneo− in horizontal and vertical activity, movement
time, rest time, and total distance. While exercised mice
showed decreased activity compared to unexercised
P448Lneo− and BL6 mice, the differences were not significant (Additional file 1: Figure S1).
Inflammation

Analysis of the skeletal muscle including the gastrocnemius, quadriceps and triceps showed an increase in inflammatory foci at 1 month of age in P448Lneo− mice
compared to control mice (Figs. 2 and 3). This difference
increases by 2 to 4 fold to a maximum inflammation at
2 months of age. The maximum amount of inflammation was noted in the quadriceps muscle. The inflammatory infiltrates then decreased at both 6 and
9 months in all 3 muscles. In P448Lneo− mice exercised until 6 months of age, the inflammatory infiltrates increase from 1.8 to 2.2 folds compared to
unexercised P448Lneo− mice (Table 4; Fig. 3).
Fibrosis

No significant differences in percent fibrosis in the quadriceps or triceps between P448Lneo− and controls were
seen at 1, 2, 6, or 9 months of age (Additional file 2:
Table S1). P448Lneo− exercised mice showed significantly increased percent fibrosis in the quadriceps muscles at 6 months of age compared to unexercised
P448Lneo− mice (p < 0.05) and controls (p < 0.001;
Table 4; Fig. 3). There were no significant differences in
the gastrocnemius and triceps between the 2 mice
groups (data not shown).
Percent central nucleation

Control BL6 mice showed between 0.2 and 1.4% central
nucleation in the quadriceps, gastrocnemius, and triceps from 1 to 9 months. P448Lneo− mice showed percent central nucleation of 9.6% at 1 month, 56% at
6 months, and 60.4% at 9 months (Table 4;
Additional file 2: Table S1). The percent central nucleation in the quadriceps and triceps were increased in 6month-old exercised P448Lneo− mice compared to unexercised mice while the quadriceps decreased slightly
(Table 4). There were differences in the variation (SD
of percent central nucleation for each mouse) of
P448Lneo− and control mice (Additional file 2: Table
S1) and P448Lneo− exercised mice showed increased
SD of percent central nucleation in the triceps compared to controls at 6 months of age (Table 4).
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Fig. 3 Histology images showing inflammation (hematoxylin and eosin staining at 20x) and fibrosis (picrosirius red staining at 10x) in the
quadriceps of P448Lneo− (FKRP), exercised P448Lneo− (FKRP-treadmill), and control (BL6) mice. Panels a–d show inflammation in BL6 mice at
1, 2, 6, and 9 months of age. Panels e–h show inflammation in FKRP mice at 1, 2, 6, and 9 months of age. Panel i shows inflammation in FKRPtreadmill mice at 6 months of age. Panels j–l show fibrosis in BL6, FKRP, and FKRP-treadmill at 6 months of age

Fiber diameter

Respiratory muscle

Figure 4 shows the fiber diameters of the quadriceps muscles for P448Lneo− mice and controls at 1, 6, and 9 months
of age. There was no difference in the average fiber size of
P448Lneo− and control BL6 mice at 1 and 6 months of age.
At 9 months of age, P448Lneo− mice have smaller average
fiber diameter compared to control BL6 (Additional file 2:
Table S1). There was a greater variation in fiber sizes (SD
of fiber size for each mouse) in P448Lneo− mice at 1 and
6 months of age compared to control BL6 (Additional file 2:
Table S1). There were no differences in fiber size, but unexercised and exercised P448Lneo− mice showed increased
SD of fiber size for each mouse compared to controls in
the quadriceps, gastrocnemius, and triceps (Table 4).

Plethysmography

Serum creatinine kinase (CK)
Serum CK was significantly increased in P448Lneo−
mice compared to control BL6 at 1, 6, and 9 months
of age (p < 0.05; Fig. 2). At 6 months of age, exercised P448Lneo− mice showed significantly increased
serum CK levels compared to BL6 controls (p < 0.05;
Table 4).

P448Lneo− mice demonstrated a reduced decline in respiratory rate over time compared to BL6 controls at
9 months of age (p < 0.001; Fig. 5). P448Lneo− mice also
showed significantly decreased tidal volumes (p < 0.001),
normalized tidal volumes (p < 0.01), and minute volumes
(p < 0.001) compared to BL6 controls at 6 and 9 months
of age. There were significant differences in plethysmography measures at 6 months that were improved
in exercised P448Lneo− mice compared to unexercised P448Lneo− including tidal volume (p < 0.001),
minute volume (p < 0.01), and normalized minute volume
(p < 0.01; Fig. 5).

Inflammation

The diaphragm of P448Lneo− mice showed the most inflammatory infiltrates at 1 month of age (p < 0.001; Figs.
6 and 7). The infiltrates decreased but remained significant compared to controls from 2 to 9 months of age
(p < 0.0.01). Exercised P448Lneo− mice showed significant inflammation that was increased compared to
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Table 4 Histological analyses for skeletal muscles and serum creatinine kinase levels among groups of P448Lneo− (FKRP) without
and with treadmill exercise (FKRP-treadmill) and control (BL6) mice at 6 months of age
Measurement

Inflammation
(foci/mm2)

% fibrosis

% central nucleation

Fiber diameter size (μm)

SD of % central nucleation

SD of fiber size

Serum creatinine kinase(μ/l)

BL6 control

FKRP

FKRP-treadmill

Significantly different groups
(adjusted p values using ANOVA
followed by post hoc analysis)

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

GAS

8

0.03 ± 0.03

8

0.5 ± 0.4

12

0.9 ± 0.3

#BL6 vs FKRP-treadmill: p < 0.0001

Quad

8

0.05 ± 0.04

8

0.6 ± 0.2

12

1.1 ± 0.5

#BL6 vs FKRP: p < 0.01,
#BL6 vs FKRP-treadmill: p < 0.0001

Triceps

8

0.04 ± 0.06

8

0.6 ± 0.4

12

1.1 ± 0.3

#BL6 vs FKRP: p < 0.01,
#BL6 vs FKRP-treadmill: p < 0.0001

Quad

8

0.29 ± 0.07

8

0.41 ± 0.18

12

0.61 ± 0.15

BL6 vs FKRP-treadmill: p < 0.001,
FKRP vs FKRP-treadmill: p < 0.05

GAS

3

0.47 ± 0.23

3

46.18 ± 5.4

3

38.44 ± 5.1

NP

Quad

3

0.2 ± 0.3

3

56.0 ± 1.9

3

51.1 ± 2.1

NP

Triceps

3

1.44 ± 1.11

3

65.71 ± 1.1

3

75.16 ± 8.4

NP

GAS

3

34.27 ± 0.7

3

37.9 ± 3.6

3

42.7 ± 2.6

NP

Quad

3

48.2 ± 5.5

3

44.8 ± 1.2

3

49.7 ± 1.6

NP

Triceps

3

37.75 ± 1.2

3

37.03 ± 1.8

3

43.70 ± 2.0

NP

GAS

3

0.5 ± 0.2

3

7.6 ± 5.4

3

10.7 ± 5.1

NP

Quad

3

0.4 ± 0.5

3

8.9 ± 3.9

3

12.6 ± 4.4

NP

Triceps

3

1.28 ± 1.1

3

15.94 ± 1.1

3

8.17 ± 8.4

NP

GAS

3

1.93 ± 0.7

3

8.5 ± 3.6

3

8.73 ± 2.6

NP

Quad

3

11.8 ± 1.3

3

20.5 ± 1.8

3

21.5 ± 1.9

NP

Triceps

3

1.93 ± 1.2

3

4.8 ± 1.8

3

6.96 ± 2.0

NP

8

254 ± 131

7

749 ± 405

12

947 ± 575

BL6 VS. FKRP-treadmill: p < 0.05

#

Kruskal-Wallis test followed by Dunn’s multiple comparison test used. Statistical measures not performed on measures with N = 3. GAS gastrocnemius, Quad
quadriceps, SD standard deviation, NP not performed

unexercised P448Lneo− mice and BL6 controls at
6 months of age (p < 0.05; Table 5).

nucleation for each mouse) among P448Lneo− exercised,
unexercised, and control mice (Table 5; Additional file 3:
Table S2).

Percent central nucleation diaphragm

Control BL6 mice showed between 2.3 and 3.7% central
nucleation in the diaphragm from 1 to 9 months of age.
1-month-old P448Lneo− mice showed 4.4% central nucleation, which increased to 34% at 9 months old (Additional file 3: Table S2). 6-month-old unexercised
P448Lneo− mice showed 25% central nucleation, and
this increased to 44% in exercised mice (Table 5). There
is no difference in the variation (SD of percent central

Diaphragm fiber diameter

Figure 8 shows the fiber diameters of the diaphragm
muscle for P448Lneo− mice and BL6 controls at 1, 6,
and 9 months of age. No differences were seen in average fiber size in the mutant mice compared to controls
in the diaphragm, but there was greater variation in fiber
sizes (SD of fiber size for each mouse) in P448Lneo−
mice at 1 and 6 months of age compared to controls

Fig. 4 Percent number of muscle fiber diameter sizes (μm) in the quadriceps muscle in P448Lneo− and control (C57) mice at 1(panel a),
6 (panel b), and 9 (panel c) months of age. Error bars indicate standard deviation
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Fig. 5 Plethysmography results in P448Lneo− (FKRP) mice, exercised P448Lneo− mice (FKRP-treadmill), and controls (BL6) at 2, 6, and 9 months
of age. Respiratory rates (panel a) are significantly less in control mice compared to FKRP. Tidal volume (panel b) and normalized tidal volume
(panel c) are significantly increased in controls. Minute volume (panel d) and normalized minute volume (panel e) show significant changes only
at 6 months. FKRP-treadmill mice only measured at 2 and 6 months. ****p < 0.0001 between BL6 and FKRP; ‡‡‡p < 0.001, ‡‡‡‡p < 0.0001, and
p < 0.001 between BL6 and FKRP/FKRP-treadmill; ^p < 0.05 among all groups. Data presented as mean ± standard deviation

Fig. 6 Significantly increased diaphragm inflammation (panel a) and fibrosis (panel b) are seen in P448Lneo− mice (FKRP) compared to controls
(BL6) at 2, 6, and 9 months of age. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 compared to BL6 control at same age. Data presented as
mean ± standard deviation
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Fig. 7 Inflammation (hematoxylin and eosin staining at 20x) and fibrosis (picrosirius red staining at 10x) in diaphragm in P448Lneo− (FKRP) and
control (BL6) mice. Panels a–d show inflammation in the diaphragm of BL6 mice at 1, 2, 6, and 9 months of age. Panels e–h show inflammation
in the diaphragm of FKRP mice at 1, 2, 6, and 9 months of age. Panels i–l show fibrosis in the diaphragm of BL6 mice at 1, 2, 6, and 9 months of
age. Panels m–p shows fibrosis in the diaphragm of FKRP mice at 1, 2, 6, and 9 months of age

Table 5 Histological analyses of the diaphragm among groups of P448Lneo− (FKRP) with and without treadmill exercise
(FKRP-treadmill) and control (BL6) mice at 6 months of age
Measurement

BL6 control

FKRP

N

Mean ± SD

N

Mean ± SD

FKRP-treadmill
N

Mean ± SD

Significantly different groups
(adjusted p values using ANOVA
followed by post hoc analysis)

Inflammation (foci/mm2)

8

0.5 ± 0.3

8

4.0 ± 0.8

12

8.7 ± 2.8

BL6 vs FKRP: p < 0.01,
BL6 vs FKRP-treadmill: p < 0.0001
FKRP vs FKRP-treadmill: p < 0.0001

% fibrosis

8

2.0 ± 0.7

8

13.7 ± 3.8

12

13.4 ± 2.2

BL6 vs FKRP: p < 0.0001,
BL6 vs FKRP-treadmill: p < 0.0001

% central nucleation

3

2.4 ± 0.4

3

24.8 ± 2.0

3

44 ± 9.4

NP

Fiber diameter size (μm)

3

24.6 ± 2.6

3

21.3 ± 1.2

3

26.7 ± 2.5

NP

SD of % central nucleation for each mouse

3

1.6 ± 1.2

3

4.9 ± 3.3

3

7.7 ± 2.3

NP

SD of fiber size for each mouse

3

4.5 ± 0.8

3

6.3 ± 0.2

3

8.1 ± 0.2

NP

Statistical analyss not performed on measures with N = 3. SD standard deviation, NP not performed
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Fig. 8 Percent number of muscle fiber diameter sizes (μm) in the diaphragm muscle in P448Lneo− and control (C57) mice at 1(panel a),
6 (panel b), and 9 (panel c) months of age. Error bars indicate standard deviation

(Additional file 3: Table S2) and between unexercised
and exercised P448Lneo− mice at 6 months of age
(Table 5).
Diaphragm fibrosis

There were no significant differences in percent fibrosis of
the diaphragm at 1 month of age; however, there was significantly increased percent fibrosis in the diaphragms of 2-, 6(unexercised and exercised), and 9-month-old P448Lneo−
mice compared to controls (p < 0.01; Table 5; Fig. 6).

Cardiac muscle
Echocardiography

Echocardiographic data collected at 2 and 6 months
were not significantly different between P448Lneo− mice
and controls except for heart rates (Additional file 4:
Table S3). At 9 months of age, there was significantly decreased systolic function measured via SF in the mutant
mice (29 ± 2%) compared to controls (31 ± 1%; p < 0.01;
Fig. 9). The left ventricular internal diameter in diastole
measured in the parasternal short axis was smaller in
P448Lneo− mice compared to controls and corresponded to smaller left ventricular volume in diastole
and a significantly decreased left ventricular stroke volume (p < 0.01). The myocardial thickness of the left ventricular infero-posterior wall was significantly increased
in P448Lneo− mice compared to controls (p < 0.0001),
and this corresponded with a significantly increased left
ventricular mass in the mutant mice (p < 0.001; Fig. 9;
Additional file 4: Table S3). The myocardial performance
index (MPI) was also noted to be significantly increased
in P448Lneo− mice compared to controls at 9 months of
age. This was related to a significantly decreased isovolumic relaxation time (IVRT) seen in the mutant mice (12.
1 ms versus 15.3 ms in controls; p < 0.04). This increase
may be related to decreased ventricular compliance.
Heart rates at 6 months of exercised P448Lneo− mice
(463 ± 40 beats per minute; BPM) and unexercised
P448Lneo− (461 ± 27 BPM) were significantly increased
compared to controls (433 ± 29 BPM; p < 0.05).

Myocardial fibrosis

There were no significant differences in myocardial fibrosis at 1, 2, and 6 months of age between P448Lneo−
mice compared to controls. There was significantly increased myocardial percent fibrosis at 9 months of age
in P448Lneo− mice (0.69 ± 0.24) compared to controls
(0.38 ± 0.17; p < 0.05; Fig. 9).
Myocardial mRNA expression

mRNA expression for natriuretic peptide type A (Nppa)
was significantly increased in P448Lneo− mice compared
to controls at 6 months (p < 0.05) and for natriuretic
peptide type B (Nppb) at 6 (p < 0.05) and 9 months of
age (p < 0.01; Fig. 10). There were no differences in
mRNA expression of fibronectin 1 (Fn1) between
P448Lneo− and control mice at all ages (Fig. 10).

Discussion
In this study, we further phenotyped the P448Lneo−
mouse model of FKRP-related limb girdle muscular dystrophy. One important aspect of this study is to better
understand and validate cardiac muscle disease in the
FKRP mutant mouse. Earlier studies reported mild effects of the disease on the histology and functions of the
cardiac muscle. Blaeser et al. [19] reported an EF 49 ±
5% in P448Lneo− and 55 ± 9% in BL6 control mice at
10 months of age, although this difference was not statistically significant. However, Blaeser et al. did find a
significant difference in EF between P448Lneo− (55 ±
5%) and BL6 (62 ± 7%) at the age of 6 months [19].
Maricelli et al. (2017) also demonstrated decreased EF
and SF at 6 months of age in male and female P448Lneo
− mice compared to controls, with female mice demonstrating more significant deficits [24]. In this current
study, we demonstrated significant decrease in systolic
cardiac function in P448Lneo− male mice compared to
BL6 at 9 months of age. P448Lneo− mice had a SF of
29% compared to 31% in controls (p < 0.01). This corresponds to an EF of 56% in P448Lneo− mice compared to
60% in controls. However, we show no significant differences in cardiac function at 6 months of age. We also
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Fig. 9 Cardiac phenotypes in P448Lneo− (FKRP) and control (BL6) mice. At 9 months of age, there was significantly decreased systolic function
measured via fractional shortening percent (FS%; panel a) and ejection fraction (EF%; panel b) in P448Lneo− mice compared to controls
(p < 0.01). FKRP-treadmill mice were only measured at 2 and 6 months. FKRP mice showed significantly increased left ventricular anterior wall
(LVAW) thickness at 6 and 9 months of age (panel c). Left ventricular posterior wall (LVPW) thickness was significantly increased in FKRP mice at
9 months (panel d). Panel e is an echo image in the parasternal short axis showing the M-mode tracing for a 9-month-old BL6 control mouse.
The left ventricular internal diameter in diastole measured 4.18 mm. Panel f is an echo image in the parasternal short axis showing the M-mode
image for a 9-month-old FKRP mouse. The left ventricular internal diameter in diastole measured 3.86 mm. FKRP mice showed a smaller left
ventricular internal diameter in diastole at 9 months of age. Picrosirius red staining of the left ventricle (panel g 10x; panel h 20x) of a control
mouse at 9 months of age shows no significant collagen staining. Picrosirius red staining of the left ventricle (panel i 10x; panel j 20x) of a FKRP
mouse at 9 months of age shows patchy, diffuse collagen staining. There was significantly increased cardiac fibrosis in 9-month-old FKRP mice
compared to controls

demonstrated increased myocardial wall thickness and
left ventricular mass at 9 months of age in P448Lneo−
mice associated with increased mRNA expression of
Nppa and Nppb [28].
Histopathology demonstrated an increase in myocardial
fibrosis. Blaeser et al. showed patchy myocardial fibrosis
that was 4% of measured area at 6 months of age and increased to about 6% at 12 months of age, compared to approximately 1% in BL6 controls [19]. The current study
also demonstrated an increase in myocardial fibrosis and

showed approximately twice the amount of fibrosis in
P448Lneo− mice compared to controls at 9 months of
age. The increasing myocardial fibrosis with age likely
leads to worsening systolic function as these mice get
older. Data from all studies are therefore consistent indicating that lack of functional glycosylation of a-DG results
in a mild but progressive degeneration and fibrosis in the
cardiac muscle. This leads to a clear trend of decrease in
cardiac systolic function. However, demonstration of significance in cardiac function between normal and mutant
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Fig. 10 Real-time PCR of Nppa (panel a), Nppb (panel b), and Fn1 (panel c) for P448Lneo− (FKRP) and control (BL6) mice at 2, 6, and 9 months of
age. Fold-changes are shown relative to 2-month-old control mice. Data are presented as mean and error bars denote SD for n = 4–6 per
group. * represents a significant difference between age-matched FKRP and BL6 mice, # represents a significant difference across age for FKRP mice

mice is dependent on age, method of detection, and likely
requires a larger cohort size.
Respiratory disease is seen in the clinical spectrum of
FKRP-mediated LGMD [29]. This was also demonstrated
in the P448Lneo− mouse model. Blaeser et al. demonstrated significant pathology in the diaphragm starting at
6 weeks of age. By 6 months of age, there were large
areas of inflammatory infiltration. By 10 and 12 months
of age, the area of fibrotic tissue increased to approximately 60% with the majority of fibers demonstrating
central nucleation [19]. An earlier study also showed severe pathology in the diaphragm with clear variation in
fiber size, the presence of necrotic fibers and central nucleation (17.6%) [16]. Maricelli et al. also showed
changes in central nucleation of the diaphragm at
3 months of age [24]. The current study confirms that
the decreased normalized tidal and minute volumes at 6
and 9 months of age correspond with increased inflammation and fibrosis in the diaphragm. We also show a
functional decline in respiration with age. Interestingly,
P448Lneo− mice demonstrated a reduced decline in respiratory rate over time. This is likely related to the fact
that older mice have reduced tidal volumes, and they
can maintain higher respiratory rates for their activity
due to the compensatory effort by the remaining muscles. However, respiratory rates in more severe dystrophic phenotypes, and perhaps also patients lacking
regeneration capacity, will likely decrease more significantly with age. Interestingly, exercised P448Lneo− mice
showed less tidal and minute volume loss compared to
unexercised mice. This may be again related to exerciserelated compensatory regeneration in the diaphragm indicated by significant increase in central nucleation
(44%) compared to unexercised mice (25%). Other potential factors, not evaluated in this study, including pulmonary inflammation and vascular function could also
be involved. Exercised mice showed significantly increased diaphragm muscle inflammation compared to
unexercised mice. This could lead to a more dramatic
decrease in respiratory function at an older age; further
studies are needed. The functional parameters of

plethysmography and associated pathologic changes in
the diaphragm make the P448Lneo− a strong model for
respiratory disease in FKRP-related LGMD.
We did not demonstrate any significant functional differences in muscle strength or activity in unexercised
P448Lneo− mice compared to controls. This is likely related to the significant evidence of skeletal muscle regeneration present in the mouse model. Blaeser et al.
showed that all limb skeletal muscles had severe degeneration (necrotic fibers) and regeneration (central nucleation) as a predominant feature with relatively limited
fibrosis [19]. Cycles of muscle degeneration and regeneration were clearly indicated by the significant variation
in fiber size and central nucleation in more than 37% of
the muscle fibers [16]. We also demonstrated increased
regeneration by percent central nucleation in the quadriceps of P448Lneo− mice at 2, 6 (both unexercised and
exercised), and 9 months of age. Interestingly, fibrosis
was limited in skeletal muscle (quadriceps and triceps)
of the unexercised mice, but was significantly increased
in exercised mice. Maricelli et al. used a modified exercise protocol, based on studies from Rocco et al. [30],
which included two sessions where mice exercised to exhaustion. This protocol elicited both functional and
histological change in exercised mice including decreased grip strength, short time to exhaustion, increased fibrosis in the diaphragm, and increased serum
CK levels of P448Lneo− mice compared to unexercised
mice and controls [24, 30]. While an optimal exercise
protocol is not yet known, degree of exercise is clearly
important to the course of disease progression, and the
P448Lneo− mice provide a model for such further
analysis.

Conclusions
This study provides more comprehensive outcome measures for the P448Lneo− mouse model of FKRP deficiency. The study shows significant decrease in cardiac
function at 9 months of age. This study is the first to
provide respiratory function data demonstrating significantly decreased tidal and minute volumes in the mouse
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model at 6 and 9 months of age. A chronic exercise
protocol demonstrated increased skeletal muscle fibrosis,
but improved respiratory function at 6 months of age in
mutant mice. Further studies are needed to better
understand the complexities of exercise on muscle pathology and disease progression. The results provide new
data on outcome measures for future preclinical drug
trials using the P448Lneo− mouse as a model system for
FKRP deficiency muscular dystrophy.

Additional files
Additional file 1: Figure S1. Behavioral activity monitoring in P448Lneo−
(FKRP), exercised P448Lneo− (FKRP-treadmill), and control (BL6) mice from 1
to 9 months of age. FKRP-treadmill mice were only measured until 6 months
of age. Panel A: vertical activity (VACTV) data; panel B: horizontal activity
(HACTV) data; panel C: total distance traveled (cm) during session (TOTDIST)
data; panel D: time (sec, seconds) spent in movement (MOVTIME); panel E:
time (sec, seconds) spent resting (RESTIME). No significant differences were
seen between groups for all measures. (TIFF 136 kb)
Additional file 2: Table S1. Histological analyses for skeletal muscles
and serum creatinine kinase levels in P448Lneo− (FKRP) and control
(BL6) mice at 1, 2, 6, and 9 months of age. (DOCX 16 kb)
Additional file 3: Table S2. Histological analyses of the diaphragm in
P448Lneo− (FKRP) and control (BL6) mice at 1, 2, 6, and 9 months of age.
(DOCX 15 kb)
Additional file 4: Table S3. Echocardiography results for P448Lneo− (FKRP)
and control (BL6) mice at 2, 6, and 9 months of age showing increased
cardiac hypertrophy and decreased systolic function at 9 months of age.
(DOCX 15 kb)
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